Company intelligence / Profile preview

SpiroChem

Ownership: Private
Development stage: Other

Overview

SpiroChem does not have its own clinical pipeline or results. It accelerates clients’ hit-to-candidate journeys by providing world-class synthetic and medicinal chemistry services that support both early discovery and process R&D. Its success rate with industry customers and academic partners positions it as a best-in-class contract research organization.

Modalities: Small moleculePeptides (including macrocycles)Fragments (high-sp^3, covalent fragments)MacrocyclesChemical libraries and scaffolds for drug discovery platforms such as DNA Encoded Libraries (DEL)
Industry: Drug Discovery Services

Partnerships

Arctoris (strategic partnership combining automated biology with SpiroChem’s advanced medicinal/synthetic chemistry platforms to offer integrated end-to-end drug discovery solutions)

Beyond the preview

Go deeper on SpiroChem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpiroChem.

Explore the full profile